Extravasation accidents with liposomal/liposomal pegylated anthracyclines treated with dexrazoxane: an overview and outcomes

The extravasation of chemotherapeutic agents is a challenge for oncologic care teams. The management of nonliposomal (conventional) anthracyclines is well established in clinical practice guidelines, including general measures and specific antidotes, such as dexrazoxane. However, there is little sci...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Anti-cancer drugs 2018-10, Vol.29 (9), p.821-826
Hauptverfasser: Caballero Romero, Álvaro, Delgado Ureña, María Teresa, Salmerón García, Antonio, Megías Fernández, María Teresa, Librada Porriño-Bustamante, María, Cabeza Barrera, José
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 826
container_issue 9
container_start_page 821
container_title Anti-cancer drugs
container_volume 29
creator Caballero Romero, Álvaro
Delgado Ureña, María Teresa
Salmerón García, Antonio
Megías Fernández, María Teresa
Librada Porriño-Bustamante, María
Cabeza Barrera, José
description The extravasation of chemotherapeutic agents is a challenge for oncologic care teams. The management of nonliposomal (conventional) anthracyclines is well established in clinical practice guidelines, including general measures and specific antidotes, such as dexrazoxane. However, there is little scientific evidence on the management of liposomal and pegylated liposomal anthracyclines. The aim of this paper was to review the scientific literature on the extravasation of liposomal and pegylated liposomal anthracyclines and determine the clinical impact of this type of extravasation, focusing on dexrazoxane. The literature was searched using two databasesPubMed and Embase. Three searches were conducted, using liposomal anthracycline extravasation, pegylated liposomal anthracycline extravasation, and liposomal doxorubicin extravasation as keywords, respectively. Seven articles fulfilled the study eligibility criteria and included seventeen cases in humans. Extravasation occurred with three drugsliposomal doxorubicin in nine (53%) patients, liposomal daunorubicin in four (23.5%) patients, and pegylated liposomal doxorubicin in four (23.5%) patients. General measures for extravasations were applied in all patients, but only three patients received dexrazoxane. All cases were completely resolved at 2–3 months, except for one patient, in whom dexrazoxane was not used. In animals, dexrazoxane decreased both the frequency of wounds produced by pegylated liposomal doxorubicin and their extent. The pharmacokinetic profiles of liposomal and pegylated liposomal anthracyclines differ from those of conventional anthracyclines, modifying their effectiveness and safety. General measures may be inadequate to heal areas affected by extravasation, which may require the administration of dexrazoxane. However, each case should be evaluated individually for the administration of dexrazoxane in off-label use until scientific evidence is available on its effectiveness and safety as an antidote for these formulations of anthracyclines.
doi_str_mv 10.1097/CAD.0000000000000672
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2075544904</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2075544904</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3052-6aea58ff5829e640d7253a2b6d008d605d84087b9c85959eaa40b7163818aa03</originalsourceid><addsrcrecordid>eNp9kE1P3DAQhq2Kqmxp_wFCOXIJTGI7drihhX5ISL1wj2bt2W7AiRfb2Y-qP74uS1HVQ-cyo9HzzsfL2GkFFxW06nJ-fXMBf0ej6jdsVgnFS6lEdcRm0Mq2FK3ix-x9jA-ZyX3-jh1zAN5ULczYz9tdCrjBiKn3Y4HG9JbGFIttn1aF69c--gHd5WtVrOn73mEiW-CYVgHN3rh-pFikQM_tZ6WlXcAffocjXWWw8BsKm562ubaFn5LxA8UP7O0SXaSPL_mE3X-6vZ9_Ke--ff46v74rDQdZlw0SSr1cSl231AiwqpYc60VjAbRtQFotQKtFa7TMHxOigIWqGq4rjQj8hJ0fxq6Df5oopm7ooyHn8nF-il0NSkohWhAZFQfUBB9joGW3Dv2AYd9V0P22vcu2d__anmVnLxumxUD2VfTH5wzoA7D1LlGIj27aUuhWhC6t_j_7FymekO4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2075544904</pqid></control><display><type>article</type><title>Extravasation accidents with liposomal/liposomal pegylated anthracyclines treated with dexrazoxane: an overview and outcomes</title><source>Journals@Ovid Complete</source><creator>Caballero Romero, Álvaro ; Delgado Ureña, María Teresa ; Salmerón García, Antonio ; Megías Fernández, María Teresa ; Librada Porriño-Bustamante, María ; Cabeza Barrera, José</creator><creatorcontrib>Caballero Romero, Álvaro ; Delgado Ureña, María Teresa ; Salmerón García, Antonio ; Megías Fernández, María Teresa ; Librada Porriño-Bustamante, María ; Cabeza Barrera, José</creatorcontrib><description>The extravasation of chemotherapeutic agents is a challenge for oncologic care teams. The management of nonliposomal (conventional) anthracyclines is well established in clinical practice guidelines, including general measures and specific antidotes, such as dexrazoxane. However, there is little scientific evidence on the management of liposomal and pegylated liposomal anthracyclines. The aim of this paper was to review the scientific literature on the extravasation of liposomal and pegylated liposomal anthracyclines and determine the clinical impact of this type of extravasation, focusing on dexrazoxane. The literature was searched using two databasesPubMed and Embase. Three searches were conducted, using liposomal anthracycline extravasation, pegylated liposomal anthracycline extravasation, and liposomal doxorubicin extravasation as keywords, respectively. Seven articles fulfilled the study eligibility criteria and included seventeen cases in humans. Extravasation occurred with three drugsliposomal doxorubicin in nine (53%) patients, liposomal daunorubicin in four (23.5%) patients, and pegylated liposomal doxorubicin in four (23.5%) patients. General measures for extravasations were applied in all patients, but only three patients received dexrazoxane. All cases were completely resolved at 2–3 months, except for one patient, in whom dexrazoxane was not used. In animals, dexrazoxane decreased both the frequency of wounds produced by pegylated liposomal doxorubicin and their extent. The pharmacokinetic profiles of liposomal and pegylated liposomal anthracyclines differ from those of conventional anthracyclines, modifying their effectiveness and safety. General measures may be inadequate to heal areas affected by extravasation, which may require the administration of dexrazoxane. However, each case should be evaluated individually for the administration of dexrazoxane in off-label use until scientific evidence is available on its effectiveness and safety as an antidote for these formulations of anthracyclines.</description><identifier>ISSN: 0959-4973</identifier><identifier>EISSN: 1473-5741</identifier><identifier>DOI: 10.1097/CAD.0000000000000672</identifier><identifier>PMID: 30036190</identifier><language>eng</language><publisher>England: Copyright Wolters Kluwer Health, Inc. All rights reserved</publisher><ispartof>Anti-cancer drugs, 2018-10, Vol.29 (9), p.821-826</ispartof><rights>Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3052-6aea58ff5829e640d7253a2b6d008d605d84087b9c85959eaa40b7163818aa03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30036190$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Caballero Romero, Álvaro</creatorcontrib><creatorcontrib>Delgado Ureña, María Teresa</creatorcontrib><creatorcontrib>Salmerón García, Antonio</creatorcontrib><creatorcontrib>Megías Fernández, María Teresa</creatorcontrib><creatorcontrib>Librada Porriño-Bustamante, María</creatorcontrib><creatorcontrib>Cabeza Barrera, José</creatorcontrib><title>Extravasation accidents with liposomal/liposomal pegylated anthracyclines treated with dexrazoxane: an overview and outcomes</title><title>Anti-cancer drugs</title><addtitle>Anticancer Drugs</addtitle><description>The extravasation of chemotherapeutic agents is a challenge for oncologic care teams. The management of nonliposomal (conventional) anthracyclines is well established in clinical practice guidelines, including general measures and specific antidotes, such as dexrazoxane. However, there is little scientific evidence on the management of liposomal and pegylated liposomal anthracyclines. The aim of this paper was to review the scientific literature on the extravasation of liposomal and pegylated liposomal anthracyclines and determine the clinical impact of this type of extravasation, focusing on dexrazoxane. The literature was searched using two databasesPubMed and Embase. Three searches were conducted, using liposomal anthracycline extravasation, pegylated liposomal anthracycline extravasation, and liposomal doxorubicin extravasation as keywords, respectively. Seven articles fulfilled the study eligibility criteria and included seventeen cases in humans. Extravasation occurred with three drugsliposomal doxorubicin in nine (53%) patients, liposomal daunorubicin in four (23.5%) patients, and pegylated liposomal doxorubicin in four (23.5%) patients. General measures for extravasations were applied in all patients, but only three patients received dexrazoxane. All cases were completely resolved at 2–3 months, except for one patient, in whom dexrazoxane was not used. In animals, dexrazoxane decreased both the frequency of wounds produced by pegylated liposomal doxorubicin and their extent. The pharmacokinetic profiles of liposomal and pegylated liposomal anthracyclines differ from those of conventional anthracyclines, modifying their effectiveness and safety. General measures may be inadequate to heal areas affected by extravasation, which may require the administration of dexrazoxane. However, each case should be evaluated individually for the administration of dexrazoxane in off-label use until scientific evidence is available on its effectiveness and safety as an antidote for these formulations of anthracyclines.</description><issn>0959-4973</issn><issn>1473-5741</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kE1P3DAQhq2Kqmxp_wFCOXIJTGI7drihhX5ISL1wj2bt2W7AiRfb2Y-qP74uS1HVQ-cyo9HzzsfL2GkFFxW06nJ-fXMBf0ej6jdsVgnFS6lEdcRm0Mq2FK3ix-x9jA-ZyX3-jh1zAN5ULczYz9tdCrjBiKn3Y4HG9JbGFIttn1aF69c--gHd5WtVrOn73mEiW-CYVgHN3rh-pFikQM_tZ6WlXcAffocjXWWw8BsKm562ubaFn5LxA8UP7O0SXaSPL_mE3X-6vZ9_Ke--ff46v74rDQdZlw0SSr1cSl231AiwqpYc60VjAbRtQFotQKtFa7TMHxOigIWqGq4rjQj8hJ0fxq6Df5oopm7ooyHn8nF-il0NSkohWhAZFQfUBB9joGW3Dv2AYd9V0P22vcu2d__anmVnLxumxUD2VfTH5wzoA7D1LlGIj27aUuhWhC6t_j_7FymekO4</recordid><startdate>20181001</startdate><enddate>20181001</enddate><creator>Caballero Romero, Álvaro</creator><creator>Delgado Ureña, María Teresa</creator><creator>Salmerón García, Antonio</creator><creator>Megías Fernández, María Teresa</creator><creator>Librada Porriño-Bustamante, María</creator><creator>Cabeza Barrera, José</creator><general>Copyright Wolters Kluwer Health, Inc. All rights reserved</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20181001</creationdate><title>Extravasation accidents with liposomal/liposomal pegylated anthracyclines treated with dexrazoxane: an overview and outcomes</title><author>Caballero Romero, Álvaro ; Delgado Ureña, María Teresa ; Salmerón García, Antonio ; Megías Fernández, María Teresa ; Librada Porriño-Bustamante, María ; Cabeza Barrera, José</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3052-6aea58ff5829e640d7253a2b6d008d605d84087b9c85959eaa40b7163818aa03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Caballero Romero, Álvaro</creatorcontrib><creatorcontrib>Delgado Ureña, María Teresa</creatorcontrib><creatorcontrib>Salmerón García, Antonio</creatorcontrib><creatorcontrib>Megías Fernández, María Teresa</creatorcontrib><creatorcontrib>Librada Porriño-Bustamante, María</creatorcontrib><creatorcontrib>Cabeza Barrera, José</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Anti-cancer drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Caballero Romero, Álvaro</au><au>Delgado Ureña, María Teresa</au><au>Salmerón García, Antonio</au><au>Megías Fernández, María Teresa</au><au>Librada Porriño-Bustamante, María</au><au>Cabeza Barrera, José</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Extravasation accidents with liposomal/liposomal pegylated anthracyclines treated with dexrazoxane: an overview and outcomes</atitle><jtitle>Anti-cancer drugs</jtitle><addtitle>Anticancer Drugs</addtitle><date>2018-10-01</date><risdate>2018</risdate><volume>29</volume><issue>9</issue><spage>821</spage><epage>826</epage><pages>821-826</pages><issn>0959-4973</issn><eissn>1473-5741</eissn><abstract>The extravasation of chemotherapeutic agents is a challenge for oncologic care teams. The management of nonliposomal (conventional) anthracyclines is well established in clinical practice guidelines, including general measures and specific antidotes, such as dexrazoxane. However, there is little scientific evidence on the management of liposomal and pegylated liposomal anthracyclines. The aim of this paper was to review the scientific literature on the extravasation of liposomal and pegylated liposomal anthracyclines and determine the clinical impact of this type of extravasation, focusing on dexrazoxane. The literature was searched using two databasesPubMed and Embase. Three searches were conducted, using liposomal anthracycline extravasation, pegylated liposomal anthracycline extravasation, and liposomal doxorubicin extravasation as keywords, respectively. Seven articles fulfilled the study eligibility criteria and included seventeen cases in humans. Extravasation occurred with three drugsliposomal doxorubicin in nine (53%) patients, liposomal daunorubicin in four (23.5%) patients, and pegylated liposomal doxorubicin in four (23.5%) patients. General measures for extravasations were applied in all patients, but only three patients received dexrazoxane. All cases were completely resolved at 2–3 months, except for one patient, in whom dexrazoxane was not used. In animals, dexrazoxane decreased both the frequency of wounds produced by pegylated liposomal doxorubicin and their extent. The pharmacokinetic profiles of liposomal and pegylated liposomal anthracyclines differ from those of conventional anthracyclines, modifying their effectiveness and safety. General measures may be inadequate to heal areas affected by extravasation, which may require the administration of dexrazoxane. However, each case should be evaluated individually for the administration of dexrazoxane in off-label use until scientific evidence is available on its effectiveness and safety as an antidote for these formulations of anthracyclines.</abstract><cop>England</cop><pub>Copyright Wolters Kluwer Health, Inc. All rights reserved</pub><pmid>30036190</pmid><doi>10.1097/CAD.0000000000000672</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0959-4973
ispartof Anti-cancer drugs, 2018-10, Vol.29 (9), p.821-826
issn 0959-4973
1473-5741
language eng
recordid cdi_proquest_miscellaneous_2075544904
source Journals@Ovid Complete
title Extravasation accidents with liposomal/liposomal pegylated anthracyclines treated with dexrazoxane: an overview and outcomes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T08%3A29%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Extravasation%20accidents%20with%20liposomal/liposomal%20pegylated%20anthracyclines%20treated%20with%20dexrazoxane:%20an%20overview%20and%20outcomes&rft.jtitle=Anti-cancer%20drugs&rft.au=Caballero%20Romero,%20%C3%81lvaro&rft.date=2018-10-01&rft.volume=29&rft.issue=9&rft.spage=821&rft.epage=826&rft.pages=821-826&rft.issn=0959-4973&rft.eissn=1473-5741&rft_id=info:doi/10.1097/CAD.0000000000000672&rft_dat=%3Cproquest_cross%3E2075544904%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2075544904&rft_id=info:pmid/30036190&rfr_iscdi=true